InvestorsHub Logo
Followers 38
Posts 2971
Boards Moderated 0
Alias Born 10/07/2012

Re: None

Wednesday, 09/02/2015 9:24:56 AM

Wednesday, September 02, 2015 9:24:56 AM

Post# of 345784
While we await the first rays from SUNRISE.....


U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Treated Non-Squamous Non-Small Cell Lung Cancer Patients

Submission based on positive results of the landmark, global Phase 3 study, CheckMate -057 evaluating overall survival versus standard of care in non-squamous non-small cell lung cancer patients

U.S. FDA grants application priority review, and Opdivo Breakthrough Therapy Designation for this indication; marks third indication for Opdivo to receive this designation

Wednesday, September 2, 2015 8:00 am EDT


http://news.bms.com/press-release/us-food-and-drug-administration-accepts-supplemental-biologics-license-application-o-0?linkId=16739957
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News